Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

Autor:	Yulong Fu, Anqi Wang, Jieqi Zhou, Wei Feng, Minhua Shi, Xiao Xu, Hongqing Zhao, Liming Cai, Jian Feng, Xuedong Lv, Xiaodong Zhang, Wenjing Xu, Zhengrong Zhang, Guoer Ma, Jian Wang, Tong Zhou, Dahai Zhao, Haohui Fang, Zeyi Liu, Jian-an Huang
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	non-small cell lung cancer liquid biopsy gene sequencing epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Frontiers in Oncology, Vol 13 (2023)
Druh dokumentu:	article
ISSN:	2234-943X
DOI:	10.3389/fonc.2023.1236311
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/6db1c64893ef43b8b5451d32f734cc3b Zobrazit plný text záznamu View record in DOAJ